Experienced in Infantile Low Calcium Level

Helen Mcdevitt

Glasgow, SCT, GB 
Experienced in Infantile Low Calcium Level
Glasgow, SCT, GB 
OverviewLocationsClinical Research

Overview

Helen Mcdevitt practices in Glasgow, United Kingdom. Ms. Mcdevitt is rated as an Experienced expert by MediFind in the treatment of Infantile Low Calcium Level. Her top areas of expertise are Achondroplasia, Acanthosis Nigricans, Multiple Sulfatase Deficiency, and Mucopolysaccharidosis Type 4 (MPS IV, Morquio Syndrome).

Her clinical research consists of co-authoring 17 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article in the study of Infantile Low Calcium Level.

Gender
Female

Locations

Glasgow, SCT, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Phase 2, Open-Label, Long-Term, Extension (OLE) Study of Infigratinib, an FGFR 1-3-Selective Tyrosine Kinase Inhibitor, in Children With Achondroplasia: PROPEL OLE
Phase 2, Open-Label, Long-Term, Extension (OLE) Study of Infigratinib, an FGFR 1-3-Selective Tyrosine Kinase Inhibitor, in Children With Achondroplasia: PROPEL OLE
Enrollment Status: Enrolling_by_invitation
Publish Date: October 06, 2025
Intervention Type: Drug
Study Drug: Infigratinib
Study Phase: Phase 2
Prospective Clinical Assessment Study in Children With Achondroplasia: The PROPEL Trial
Prospective Clinical Assessment Study in Children With Achondroplasia: The PROPEL Trial
Enrollment Status: Active_not_recruiting
Publish Date: April 11, 2025
Phase 2, Open-Label, Dose-Escalation and Dose-Expansion Study of Infigratinib, an FGFR 1-3-Selective Tyrosine Kinase Inhibitor, in Children With Achondroplasia: PROPEL 2
Phase 2, Open-Label, Dose-Escalation and Dose-Expansion Study of Infigratinib, an FGFR 1-3-Selective Tyrosine Kinase Inhibitor, in Children With Achondroplasia: PROPEL 2
Enrollment Status: Completed
Publish Date: March 26, 2025
Intervention Type: Drug
Study Drug: Infigratinib
Study Phase: Phase 2
View 2 Less Clinical Trials

17 Total Publications

Acceptability and Barriers of Exercise in Children With Osteogenesis Imperfecta.
Acceptability and Barriers of Exercise in Children With Osteogenesis Imperfecta.
Journal: Archives of rehabilitation research and clinical translation
Published: September 22, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Mcdevitt's expertise for a condition
ConditionClose
    View All 9 Advanced Conditions
    View All 8 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile